Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)
Just - Evotec Biologics, part of Evotec SE, has opened its J.POD® Toulouse, France (EU) facility, marking a significant milestone in biologics manufacturing. This 15,000 sqm facility is the first of its kind in Europe, utilizing advanced continuous manufacturing technology to provide flexible and cost-effective clinical and commercial biologics production.
The facility was built in just 18 months and can produce up to 2 metric tons of biotherapeutics. It features quality control and process development labs, a warehouse, and collaborative office spaces. The J.POD® technology offers a paradigm shift in biomanufacturing, addressing challenges in scaling from clinical to commercial production.
The project received support from the French government, Occitanie Region, Bpifrance, Haute-Garonne prefecture, and Toulouse Métropole. It aims to make biotherapeutics more accessible worldwide while offering enhanced environmental sustainability.
Just - Evotec Biologics, parte di Evotec SE, ha aperto la sua struttura J.POD® Toulouse, Francia (UE), segnando un traguardo significativo nella produzione di biologici. Questa struttura di 15.000 mq è la prima del suo genere in Europa, utilizzando una avanzata tecnologia di produzione continua per fornire una produzione flessibile e conveniente di biologici clinici e commerciali.
La struttura è stata costruita in appena 18 mesi e può produrre fino a 2 tonnellate metriche di bioterapeutici. È dotata di laboratori di controllo qualità e sviluppo dei processi, un magazzino e spazi per uffici collaborativi. La tecnologia J.POD® offre un cambiamento di paradigma nella biomanufactura, affrontando le sfide nel passaggio dalla produzione clinica a quella commerciale.
Il progetto ha ricevuto supporto dal governo francese, dalla Regione Occitanie, da Bpifrance, dalla prefettura di Haute-Garonne e da Toulouse Métropole. Mira a rendere i bioterapeutici più accessibili a livello mondiale, offrendo al contempo una maggiore sostenibilità ambientale.
Just - Evotec Biologics, parte de Evotec SE, ha inaugurado su instalación J.POD® Toulouse, Francia (UE), marcando un hito importante en la fabricación de productos biológicos. Esta instalación de 15,000 m² es la primera de su tipo en Europa, utilizando una avanzada tecnología de fabricación continua para proporcionar una producción flexible y rentable de productos biológicos clínicos y comerciales.
La instalación fue construida en solo 18 meses y puede producir hasta 2 toneladas métricas de bioterapéuticos. Cuenta con laboratorios de control de calidad y desarrollo de procesos, un almacén y espacios de oficinas colaborativas. La tecnología J.POD® ofrece un cambio de paradigma en la biomanufactura, abordando los desafíos de la escalabilidad de la producción clínica a la comercial.
El proyecto recibió apoyo del gobierno francés, la Región de Occitania, Bpifrance, la prefectura de Haute-Garonne y Toulouse Métropole. Su objetivo es hacer que los bioterapéuticos sean más accesibles a nivel mundial, al tiempo que ofrece una mayor sostenibilidad medioambiental.
Just - Evotec Biologics, Evotec SE의 일원, 프랑스 툴루즈에 위치한 J.POD® 시설을 개소하였습니다. 이는 생물학적 제품 제조에서 중요한 이정표가 됩니다. 이 15,000 제곱미터 규모의 시설은 유럽 첫 번째로, 연속 제조 기술을 활용하여 유연하고 비용 효율적인 임상 및 상업적 생물학적 제품 생산을 제공합니다.
이 시설은 단 18개월 만에 건설되었으며, 최대 2메트릭톤의 생물 치료제를 생산할 수 있습니다. 품질 관리 및 프로세스 개발 실험실, 창고, 공동 작업 공간 등이 갖추어져 있습니다. J.POD® 기술은 생물 제조에서의 패러다임 변화를 가져오며, 임상에서 상업 생산으로의 확장 문제를 해결하는 데 중점을 두고 있습니다.
이 프로젝트는 프랑스 정부, 오키타니 지역, Bpifrance, 오뜨가론 주 및 툴루즈 메트로폴의 지원을 받았습니다. 생물 치료제를 전 세계적으로 더 접근 가능하게 만들고, 동시에 환경 지속 가능성을 강화하는 것을 목표로 하고 있습니다.
Just - Evotec Biologics, filiale d'Evotec SE, a ouvert son établissement J.POD® Toulouse, France (UE), marquant une étape importante dans la fabrication de biologiques. Cet établissement de 15 000 m² est le premier de ce type en Europe, utilisant une technologie de fabrication continue avancée pour offrir une production flexible et rentable de biologiques cliniques et commerciaux.
L'établissement a été construit en seulement 18 mois et peut produire jusqu'à 2 tonnes métriques de biothérapeutiques. Il dispose de laboratoires de contrôle qualité et de développement de processus, d'un entrepôt et d'espaces de bureaux collaboratifs. La technologie J.POD® offre un changement de paradigme dans la biomanufacture, en s'attaquant aux défis liés à la montée en échelle de la production clinique à la production commerciale.
Le projet a reçu le soutien du gouvernement français, de la région Occitanie, de Bpifrance, de la préfecture de Haute-Garonne et de Toulouse Métropole. Il vise à rendre les biothérapeutiques plus accessibles à l'échelle mondiale tout en offrant une durabilité environnementale améliorée.
Just - Evotec Biologics, Teil von Evotec SE, hat seine J.POD® Toulouse, Frankreich (EU) Anlage eröffnet, was einen bedeutenden Meilenstein in der Herstellung von Biologika darstellt. Diese 15.000 m² große Anlage ist die erste ihrer Art in Europa und nutzt eine fortschrittliche technologie zur kontinuierlichen Herstellung, um flexible und kosteneffektive klinische und kommerzielle Biologika-Produktion anzubieten.
Die Anlage wurde in nur 18 Monaten gebaut und kann bis zu 2 metrische Tonnen von Biotherapeutika produzieren. Sie verfügt über Labore für Qualitätskontrolle und Prozessentwicklung, ein Lagerhaus und kooperative Büroräume. Die J.POD®-Technologie bietet einen Paradigmenwechsel in der Biomanufactur, indem sie die Herausforderungen der Skalierung von der klinischen zur kommerziellen Produktion angeht.
Das Projekt erhielt Unterstützung von der französischen Regierung, der Region Okzitanien, Bpifrance, der Präfektur Haute-Garonne und Toulouse Métropole. Ziel ist es, Biotherapeutika weltweit zugänglicher zu machen und gleichzeitig die Umweltverträglichkeit zu verbessern.
- Opening of J.POD® Toulouse facility, bringing advanced biologics manufacturing capacity to Europe
- Facility built in only 18 months, significantly faster than conventional biologics manufacturing facilities
- Capacity to produce up to 2 metric tons of biotherapeutics
- J.POD® technology enables flexible quantities and reduces manufacturing costs
- Facility constructed at a fraction of the cost compared to similar large-scale manufacturing facilities
- None.
The opening of J.POD® Toulouse represents a significant milestone for Evotec SE. This
The J.POD® facility in Toulouse is a game-changer for biologic manufacturing. Its continuous manufacturing approach addresses key industry pain points: scale-up risks and high production costs. The ability to produce up to 2 metric tons of biotherapeutics in a compact 15,000 sqm facility is remarkable. The 18-month construction time is impressively short for this industry. The facility's environmental sustainability features align with growing ESG concerns. However, the true test will be in regulatory approvals and consistent product quality at commercial scale. If successful, this could reshape biomanufacturing economics and accessibility.
Evotec's J.POD® technology addresses a critical market need for flexible, cost-effective biologics manufacturing. The European facility strengthens Evotec's competitive position in a growing market. With biologics becoming increasingly important in treating various indications, this capacity expansion is timely. The modular approach allows Evotec to adapt quickly to market demands, potentially capturing a larger market share. However, success depends on client adoption and regulatory acceptance of this novel manufacturing method. Investors should watch for partnership announcements and utilization rates as key indicators of market reception and potential revenue growth.
J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Just - Evotec Biologics' J.POD® technology offers a paradigm shift in biomanufacturing with cost-effective and flexible clinical and commercial supply solutions
HAMBURG, GERMANY and TOULOUSE, FRANCE / ACCESSWIRE / September 20, 2024 / Just - Evotec Biologics, the biologics segment of Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(NASDAQ:EVO), today celebrated the Grand Opening of its J.POD® biologics development and manufacturing facility located on Evotec's Campus Curie in Toulouse, France. The J.POD® facility in Toulouse, the second of its kind and the first in Europe, utilizes Just - Evotec Biologics' adaptable J.POD® technology to provide essential clinical and commercial biologics manufacturing capacity.
During a ceremony on Campus Curie, Pierre-André Durand, Prefect of Haute-Garonne and Occitanie, Jean-Luc Moudenc, President of Toulouse Métropole and Mayor of Toulouse as well as Jalil Benabdillah, Vice-President, Economy, Employment, Innovation and Reindustrialisation of the Occitanie region, joined the Management of Evotec and Just - Evotec Biologics, to inaugurate the new facility.
Dr Christian Wojczewski, Chief Executive Officer of Evotec, commented: "J.POD® is a bioprocessing facility by Just - Evotec Biologics that uses advanced technology to fulfill its mission of making biotherapeutics more accessible worldwide. The opening of J.POD® Toulouse, France (EU), our first J.POD® on European ground, represents a proud moment and a significant milestone for our Company. We are very thankful for the support from the French government, the Occitanie Region, Bpifrance, the Haute-Garonne prefecture, and Toulouse Métropole for helping us achieve this milestone at our Campus Curie in Toulouse. We also want to give special credit to our dedicated team, whose hard work and commitment made this possible."
J.POD® Toulouse, France (EU) brings much-needed biologics manufacturing capacity to Europe. Biologics offer a potent therapeutic solution applicable to various indications. However, conventional fed-batch manufacturing poses significant hurdles, particularly during the transition from clinical to commercial scale. The J.POD® technology, with its modular continuous manufacturing approach, enables highly intensified cGMP production of biologics at flexible quantities, effectively mitigating scale-up risks and reducing manufacturing costs.
Built in a short 18 months green field project, the approx. 15,000 sqm J.POD® facility stands out in the industry due to its cutting-edge continuous manufacturing technologies in a small, simple facility design built in significantly shorter construction time compared to conventional biologics manufacturing that can deliver up to 2 metric tons of biotherapeutics. The site features dedicated quality control and process development labs for both clinical and commercial products, along with a warehouse and collaborative office spaces. The facility is designed with enhanced environmental sustainability, resulting in reduced water, electricity, and chemical usage compared to conventional facilities.
J.POD® facilities are constructed at a fraction of the cost compared to similar large-scale DS manufacturing facilities in the industry. This significant cost advantage, with benchmark costs for comparable facilities around
Dr Linda Zuckerman, EVP and Global Head of Biotherapeutics at Just - Evotec Biologics, commented: "J.POD® is an innovative technology that not only scales biologics manufacturing but also ensures availability precisely where it's needed. With this second facility, we extend our capacity to discover and develop groundbreaking biologics but also, with our partners, deliver them promptly to patients in need. Our Toulouse-based team at Just - Evotec Biologics deserves immense credit for bringing the J.POD facility and its capabilities to France and the EU."
The construction of J.POD® Toulouse, France (EU) benefits from French government funding as part of the Investments for the future Programme (programme d'investissements d'avenir in French) and is also supported economically by the Occitanie Region.
About Just - Evotec Biologics
Just - Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch. The Just - Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics. Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com.
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Media
Gabriele Hansen
SVP Head of Global Corporate Communications
Gabriele.Hansen@evotec.com
Hinnerk Rohwedder
Director of Global Corporate Communications
Hinnerk.Rohwedder@evotec.com
Joséphine Pröhl
Corporate Communications Associate (France)
Josephine.Proehl@evotec.com
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on accesswire.com
FAQ
What is the capacity of the new J.POD® Toulouse facility?
How long did it take to build the J.POD® Toulouse facility?
What are the advantages of J.POD® technology for biologics manufacturing?
How does the cost of building a J.POD® facility compare to conventional facilities?
What impact might the opening of J.POD® Toulouse have on Evotec's stock (EVO)?
